A carregar...
SAT-100 Trial-in-Progress: ZEPHYR, a Pivotal Phase 2b/3 Randomized, Placebo-Controlled Study of Livoletide, a Novel Unacylated Ghrelin Analog, for the Treatment of Hyperphagia and Food-Related Behaviors in Patients with Prader-Willi Syndrome
Background: Prader-Willi syndrome (PWS) is a rare and complex endocrine disease characterized by hyperphagia and abnormal food-related behaviors that contribute to severe morbidity and early mortality and to a significant burden on patients and caregivers. There is no approved treatment for hyperpha...
Na minha lista:
Publicado no: | J Endocr Soc |
---|---|
Main Authors: | , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Endocrine Society
2019
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6552513/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-100 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|